Superworth

Compass Therapeutics CMPX

Biotechnology, Healthcare
$0.77
−2.42%
Market cap
$138.2M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
−40.8%

Charts

Financials

Income statement for CMPX, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$0$0n/a$850K$0$0n/a$0$0$0n/an/a
R&D$8.8M−10%$12.4M+25%$9.5M+43%$11.2M+9%$8.6M−3%$13M+5%$13.1M+37%$16.4M+47%$12.8M+49%$13.7M+5%$13.4M+3%$19.6M+19%
SG&A$3.1M+10%$3M+0%$3.2M+6%$4.7M+52%$3.6M+17%$3.5M+19%$4.9M+51%$4.7M−2%$3M−18%$4.3M+22%$6.9M+41%$7.4M+59%
−$11.9M−5%−$15.4M+19%−$12.8M+32%−$15M+13%−$12.2M+3%−$16.6M+8%−$18M+41%−$21.1M+40%−$15.8M+29%−$18M+9%−$20.3M+13%−$27M+28%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income−$10M−17%−$13.4M+16%−$10.8M+38%−$13.1M+16%n/an/a−$16.6M+54%n/an/an/an/an/a
$0$0$0$0n/an/a$0n/an/an/an/an/a
Net income−$10M−17%−$13.4M+16%−$10.8M+38%−$13.1M+16%−$10.5M+5%−$15M+12%−$16.6M+54%−$19.9M+52%−$14.3M+36%−$15.7M+5%−$18.3M+10%−$25.2M+27%
n/an/an/an/a−$0.08−$0.11−$0.12n/an/an/an/an/a
n/an/an/an/a137.6M137.7M138.2Mn/an/an/an/an/a

EPS, diluted: 6 periods, Q4 FY19 to Q1 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q4 FY19 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Compass Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CMPXCompass Therapeutics$138.2Mn/mn/an/mn/mn/m
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
CYHCommunity Health Systems$296.2M8.1×4.5×0.0×−8%0.3%
Peer median$208.9M15.3×20.5×2.1×+6%4.8%

More on Compass Therapeutics

Each number over time

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .